News & Perspective

Dec 19, 2011

Dec 19, 2011

Signs of Tamiflu-resistant 2009 H1N1 flu transmission cited

(CIDRAP News) – An analysis of 2009 H1N1 influenza virus isolates from the 2010-11 flu season suggests that low-level community transmission of an oseltamivir-resistant strain took place, a development that bears close watching, researchers reported today.

Nov 10, 2011

Nov 10, 2011

UK unveils tiered flu pandemic plan

(CIDRAP News) – The United Kingdom today released an update of its flu pandemic plan, which for the first time addresses three varying levels of impact.

The revision updates the region's 2007 plan, and many of the changes revolve around lessons learned during the 2009 H1N1 pandemic and the latest scientific evidence, the Department of Health said in a press release.

Aug 26, 2011

Aug 26, 2011

Australia reports oseltamivir-resistant 2009 H1N1 cluster

(CIDRAP News) – Australian public health officials yesterday reported a cluster of oseltamivir (Tamiflu)-resistant 2009 H1N1 infections, one of the largest to date, centered in one region of New South Wales state.

Aug 08, 2011

Aug 08, 2011

Study puts global 2009 H1N1 infection rate at 11% to 21%

(CIDRAP News) – Researchers who combed through scores of serologic studies estimate that the global cumulative incidence of pandemic H1N1 influenza infection before vaccines became available was probably below 20%, far lower than the 50% that pandemic planners had envisioned as a possible worst case.

Jul 13, 2011

Jul 13, 2011

Study: Adjuvanted H1N1 vaccines had little effect on GBS risk

(CIDRAP News) – A five-country study from Europe indicates that the use of adjuvanted vaccines against the pandemic H1N1 influenza virus probably did not increase the risk of Guillain-Barre syndrome (GBS), but the investigators could not firmly rule out a slightly greater chance of suffering the paralytic condition.

Pages

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»